P

    Pelthos Therapeutics Inc. (PTHS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $23.88
    -0.85 (-3.44%)

    Market Cap: $92.19M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    29%(2/7)
    Avg Surprise
    -137.51%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-3.34
    Range$-4.60 - $-1.60
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-1.89+43.3%
    60d ago$-1.89+43.3%
    30d ago$-1.89+43.3%
    7d ago$-3.34+0.0%
    Current$-3.34
    Revenue Consensus
    $18M
    Range$17M - $21M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-8.95
    Range$-17.58 - $-2.53
    4 analysts
    Revenue Consensus
    $20M
    Range$12M - $28M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-8.95---
    Sep 26EST
    		-$-3.34---
    Jun 26
    Reported Aug 13
    		$-6.62$-3.02-119.21%Miss-23.0%
    Mar 26
    Reported May 14
    		$-4.66$-3.58-30.24%Miss-45.2%
    Dec 25
    Reported Mar 19
    		$-2.69$-4.18+35.65%Beat-740.6%
    Sep 25
    Reported Nov 13
    		$-5.30$-0.57-829.82%Miss-82.8%
    Jun 25
    Reported Aug 13
    		$-5.38$-6.26+14.06%Beat-73.5%
    Mar 25
    Reported May 28
    		$-3.21N/AN/ABeat+41.6%
    Dec 24
    Reported Feb 26
    		$-0.32$0.00N/AMiss-
    Sep 24
    Reported Nov 13
    		$-2.90$-2.30-26.09%Miss-
    Jun 24
    Reported Aug 13
    		$-3.10$-2.90-6.90%Miss-
    Mar 24
    Reported May 29
    		$-5.50N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.24EV/EBITDA-3.58x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-199.50%Operating Margin-101.40%
    ROE-333.80%ROIC-95.75%
    Financial Health
    Debt/Equity-46.58xInterest Coverage-3.14x
    Current Ratio1.98xQuick Ratio1.31x
    Trading Statistics
    Beta3.13Avg Volume66.25K
    52-Week High$37.5052-Week Low$18.19

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$25.83
    SMA 20$27.01
    SMA 50$27.13
    SMA 200$25.60
    EMA 10$25.76
    EMA 20$26.40
    EMA 50$26.73
    EMA 200$25.57

    MACD

    Line: -0.63Signal: -0.29Hist: -0.34

    ADX

    ADX: 15.6+DI: 11.4-DI: 18.1

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down100.0
    PSAR$27.20

    Bollinger Bands

    Upper Band$30.24
    Lower Band$23.78
    %B Position2391%(Upper)
    Band Width0.01

    RSI (14-Day)

    Neutral
    38.1

    Momentum Oscillators

    Stoch %K10.4
    Stoch %D21.6
    Williams %R-90.7
    ROC (10d)-7.8%
    Momentum-2.02
    CCI (20d)-168.4
    MFI (14d)14.7

    Volatility Measures

    ATR (14d)$2.12(8.9%)
    StdDev (20d)1.61
    Hist Vol57.3%(High)

    Volume Flow

    VWAP$24.38
    OBV42.1M
    AD Line2.7B
    CMF (20d)-0.060

    Volume Metrics

    Avg Vol (20d)50.8K
    Vol Ratio1.6x(High)
    VWMA (20d)$26.87

    Pivot Points

    R3$27.55
    R2$26.69
    R1$25.71
    Pivot Point$24.86
    S1$23.88
    S2$23.02
    S3$22.04

    Advanced Oscillators

    TSI-9.59
    Ultimate Osc38.1
    KST-35.98

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$15.60M$10.91M$9.39M$7.41M$0$0$-3,527$0$3,527$0N/A$0
    Cost of Revenue$3.61M$1.67M$1.67M$2.32M$0$0N/A$0$0$0N/A$0
    Gross Profit$11.99M$9.23M$7.72M$5.09M$0$0$-3,527$0$3,527$0N/A$0
    Operating Expenses$29.32M$22.32M$19.72M$20.45M$3.23M$1.83M$1.82M$2.05M$1.76M$1.93M$3.88M$1.29M
    R&D$600,000$186,000$373,888$145,000$515,000$194,000$284,439$415,000$12,955$466,606$2.29M$49,132
    SG&A$27.67M$21.10M$18.47M$19.63M$2.72M$1.64M$1.54M$1.63M$1.75M$1.47M$1.58M$1.24M
    Operating Income$-17,323,000$-13,088,000$-12,003,600$-15,362,000$-3,231,000$-1,834,000$-1,823,932$-2,049,000$-1,764,086$-1,933,982$-3,878,815$-1,291,726
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2.39M$2.35M$16.58M$1.35M$218,000$134,000$102,119$39,000$7,533$628,348$160,338$130,006
    Income Before Tax$-23,417,000$-25,073,000$-28,586,450$-16,703,000$-3,449,000$-1,968,000$-1,926,051$-1,695,000$-1,771,619$-2,562,330$-4,039,153$-1,421,732
    Income Tax Expense$0$0$-6,922,000$-465,000$0$0$0$0$0$0$0$0
    Net Income$-23,417,000$-25,073,000$-21,664,450$-16,238,000$-3,449,000$-1,968,000$-1,926,051$-1,695,000$-1,771,619$-2,562,330$-4,039,153$-1,421,732
    EBITDA$-19,402,000$-20,955,000$-10,786,600$-14,603,891$-3,066,000$-1,740,000$-1,747,932$-1,645,630$-1,764,086$-1,328,352$-3,757,482$-1,274,062
    EBIT$-21,028,000$-22,720,000$-12,003,600$-15,357,000$-3,231,000$-1,834,000$-1,823,932$-1,656,000$-1,764,086$-1,933,982$-3,878,815$-1,291,726
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PTHS

    News

    Channel Therapeutics Corp (CHRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages

    This article provides a technical analysis of Channel Therapeutics Corp (CHRO), focusing on its stock indicators and moving averages. While specific support and resistance data are not disclosed, the analysis includes insights from various technical indicators like MACD, RSI, and KDJ, alongside moving average signals. The overall technical rating suggests a "Buy" signal based on the combined analysis of these metrics.

    TradingKey•6/22/26•
    Neutral

    Channel Therapeutics Corp (CHRO) Institutional Confidence

    This article provides an overview of Channel Therapeutics Corp (CHRO) stock, focusing on its institutional confidence and shareholding activity. It lists key institutional investors, their shareholdings, and the percentage change in their holdings. The company's current stock price, market cap, and a brief financial overview are also mentioned.

    TradingKey•6/19/26•
    Neutral

    Channel Therapeutics Corp (CHRO) Valuation: PE, PB & Fair Value Analysis

    This article provides a valuation analysis for Channel Therapeutics Corp (CHRO), listing its current stock price and market capitalization. It highlights that key valuation metrics such as P/E, P/B, P/S, and P/CF ratios are not yet disclosed by the company. The page serves as a placeholder for financial data and analysis on the TradingKey platform.

    TradingKey•6/19/26•
    Neutral

    Channel Therapeutics (CHRO) Stock News

    This page provides news and updates for Channel Therapeutics (CHRO), which has transitioned into Pelthos Therapeutics. The news covers the commercial launch of ZELSUVMI for molluscum contagiosum, the merger with Channel Therapeutics, a reverse stock split, and Channel Therapeutics' historical preclinical work on non-opioid pain therapeutics targeting NaV1.7.

    Stock Titan•6/4/26•
    Bullish

    Frequently Asked Questions About PTHS

    Does PTHS pay dividends?
    Pelthos Therapeutics Inc. (PTHS) does not currently pay a regular dividend.
    What is PTHS's market cap?
    Pelthos Therapeutics Inc. (PTHS) has a market capitalization of $92.19M with a current stock price of $23.88.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In